Header Logo

Connection

Philip Bonomi to Female

This is a "connection" page, showing publications Philip Bonomi has written about Female.
Connection Strength

1.084
  1. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis. Curr Med Res Opin. 2020 09; 36(9):1497-1505.
    View in: PubMed
    Score: 0.055
  2. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9.
    View in: PubMed
    Score: 0.041
  3. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9.
    View in: PubMed
    Score: 0.038
  4. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92.
    View in: PubMed
    Score: 0.037
  5. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
    View in: PubMed
    Score: 0.033
  6. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.033
  7. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.031
  8. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.030
  9. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.028
  10. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74.
    View in: PubMed
    Score: 0.026
  11. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.025
  12. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
    View in: PubMed
    Score: 0.024
  13. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
    View in: PubMed
    Score: 0.023
  14. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
    View in: PubMed
    Score: 0.023
  15. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22.
    View in: PubMed
    Score: 0.022
  16. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
    View in: PubMed
    Score: 0.021
  17. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
    View in: PubMed
    Score: 0.018
  18. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.014
  19. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb; 18(3):623-31.
    View in: PubMed
    Score: 0.013
  20. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
    View in: PubMed
    Score: 0.013
  21. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.012
  22. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72.
    View in: PubMed
    Score: 0.012
  23. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
    View in: PubMed
    Score: 0.012
  24. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.012
  25. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):781-96.
    View in: PubMed
    Score: 0.012
  26. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-123-S12-129.
    View in: PubMed
    Score: 0.011
  27. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.011
  28. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
    View in: PubMed
    Score: 0.011
  29. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
    View in: PubMed
    Score: 0.011
  30. Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):102-7.
    View in: PubMed
    Score: 0.011
  31. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.010
  32. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.010
  33. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol. 1995 Aug; 22(4 Suppl 9):42-7.
    View in: PubMed
    Score: 0.010
  34. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun; 12(3):199-220.
    View in: PubMed
    Score: 0.010
  35. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.009
  36. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by?Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8.
    View in: PubMed
    Score: 0.009
  37. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.009
  38. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1994 Jun; 17(3):215-7.
    View in: PubMed
    Score: 0.009
  39. Alteration of integrated optical density and intercellular structure after induction chemotherapy and survival in lung carcinoma patients treated surgically. Anal Quant Cytol Histol. 1994 Feb; 16(1):18-24.
    View in: PubMed
    Score: 0.009
  40. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.009
  41. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57.
    View in: PubMed
    Score: 0.009
  42. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol. 1993 Aug; 16(4):342-5.
    View in: PubMed
    Score: 0.008
  43. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.008
  44. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.008
  45. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21.
    View in: PubMed
    Score: 0.008
  46. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992 Jul 15; 84(14):1077-84.
    View in: PubMed
    Score: 0.008
  47. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9.
    View in: PubMed
    Score: 0.008
  48. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.007
  49. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.007
  50. Prognostic importance of subdividing clinically staged IIIa and IIIb patients with non-small-cell lung cancer. J Clin Oncol. 1991 Feb; 9(2):357-9.
    View in: PubMed
    Score: 0.007
  51. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):247-52.
    View in: PubMed
    Score: 0.007
  52. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16.
    View in: PubMed
    Score: 0.007
  53. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.007
  54. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.007
  55. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.007
  56. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.007
  57. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Sep; 34(3):357-9.
    View in: PubMed
    Score: 0.006
  58. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.006
  59. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
    View in: PubMed
    Score: 0.006
  60. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.006
  61. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
    View in: PubMed
    Score: 0.006
  62. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol. 1988 Apr; 15(2 Suppl 1):26-33.
    View in: PubMed
    Score: 0.006
  63. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
    View in: PubMed
    Score: 0.006
  64. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study. Am J Clin Oncol. 1988 Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.006
  65. Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4.
    View in: PubMed
    Score: 0.006
  66. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
    View in: PubMed
    Score: 0.006
  67. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55.
    View in: PubMed
    Score: 0.006
  68. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
    View in: PubMed
    Score: 0.005
  69. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006 Nov; 81(2):163-7.
    View in: PubMed
    Score: 0.005
  70. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83.
    View in: PubMed
    Score: 0.005
  71. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9.
    View in: PubMed
    Score: 0.005
  72. Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide. Cancer Treat Rep. 1985 Sep; 69(9):1007-9.
    View in: PubMed
    Score: 0.005
  73. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 01; 23(25):5883-91.
    View in: PubMed
    Score: 0.005
  74. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug; 3(8):1079-85.
    View in: PubMed
    Score: 0.005
  75. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin Oncol. 1985 Mar; 12(1 Suppl 1):48-54.
    View in: PubMed
    Score: 0.005
  76. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
    View in: PubMed
    Score: 0.005
  77. Metastatic breast cancer from an occult primary provisionally identified by steroid receptor content and two-dimensional protein electrophoresis: some problems associated with the use of the latter technique. Clin Physiol Biochem. 1985; 3(5):265-70.
    View in: PubMed
    Score: 0.005
  78. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01; 23(1):175-83.
    View in: PubMed
    Score: 0.005
  79. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
    View in: PubMed
    Score: 0.004
  80. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer Treat Rep. 1983 Feb; 67(2):197-8.
    View in: PubMed
    Score: 0.004
  81. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
    View in: PubMed
    Score: 0.004
  82. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95.
    View in: PubMed
    Score: 0.004
  83. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002 Feb 06; 94(3):173-81.
    View in: PubMed
    Score: 0.004
  84. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000 Jun; 11(6):673-8.
    View in: PubMed
    Score: 0.003
  85. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000 May; 66(5):432-6; discussion 436-7.
    View in: PubMed
    Score: 0.003
  86. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5.
    View in: PubMed
    Score: 0.003
  87. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.003
  88. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999 Apr; 5(4):767-74.
    View in: PubMed
    Score: 0.003
  89. Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas. Cancer Treat Rep. 1978 Aug; 62(8):1211-3.
    View in: PubMed
    Score: 0.003
  90. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
    View in: PubMed
    Score: 0.003
  91. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.
    View in: PubMed
    Score: 0.003
  92. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1995 Jul; 13(7):1615-22.
    View in: PubMed
    Score: 0.002
  93. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41.
    View in: PubMed
    Score: 0.002
  94. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer. 1994 May 15; 73(10):2599-606.
    View in: PubMed
    Score: 0.002
  95. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1993 May; 11(5):879-84.
    View in: PubMed
    Score: 0.002
  96. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 24(1):17-23.
    View in: PubMed
    Score: 0.002
  97. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol. 1990 Sep; 38(3):323-7.
    View in: PubMed
    Score: 0.002
  98. Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92.
    View in: PubMed
    Score: 0.002
  99. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989 May; 47(5):669-75; discussion 676-7.
    View in: PubMed
    Score: 0.002
  100. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988 Dec; 104(6):1080-9.
    View in: PubMed
    Score: 0.002
  101. Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
    View in: PubMed
    Score: 0.001
  102. Megestrol acetate as primary hormonal therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):34-7.
    View in: PubMed
    Score: 0.001
  103. Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):38-43.
    View in: PubMed
    Score: 0.001
  104. Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):323-5.
    View in: PubMed
    Score: 0.001
  105. Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer. NCI Monogr. 1988; (6):327-9.
    View in: PubMed
    Score: 0.001
  106. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer. 1987 Mar 15; 59(6):1170-2.
    View in: PubMed
    Score: 0.001
  107. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg. 1987 Jan; 43(1):87-91.
    View in: PubMed
    Score: 0.001
  108. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol. 1986 Dec; 13(4 Suppl 4):9-14.
    View in: PubMed
    Score: 0.001
  109. Megestrol acetate: first-line therapy for advanced breast cancer. Semin Oncol. 1986 Dec; 13(4 Suppl 4):15-9.
    View in: PubMed
    Score: 0.001
  110. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study. Cancer Treat Rep. 1986 Feb; 70(2):293-4.
    View in: PubMed
    Score: 0.001
  111. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
    View in: PubMed
    Score: 0.001
  112. Remission of invasive thymoma due to chemotherapy. Two patients treated with cyclophosphamide, doxorubicin, and vincristine. Chest. 1985 Mar; 87(3):377-80.
    View in: PubMed
    Score: 0.001
  113. A ten year experience with hepatic resection. Surg Gynecol Obstet. 1984 Sep; 159(3):223-8.
    View in: PubMed
    Score: 0.001
  114. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1984 Sep; 68(9):1163-5.
    View in: PubMed
    Score: 0.001
  115. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep. 1983 Jul-Aug; 67(7-8):717-20.
    View in: PubMed
    Score: 0.001
  116. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep. 1982 Jun; 66(6):1417-9.
    View in: PubMed
    Score: 0.001
  117. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother Pharmacol. 1982; 9(1):41-4.
    View in: PubMed
    Score: 0.001
  118. Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 1981 Aug; 12(1):120-8.
    View in: PubMed
    Score: 0.001
  119. Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy. Anticancer Res. 1981; 1(6):335-40.
    View in: PubMed
    Score: 0.001
  120. Stabilization of human breast cancer progesterone (5020) receptor by sodium molybdate. Clin Chim Acta. 1980 May 09; 103(3):367-73.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.